CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Discover what to know about cash back and taxes to manage your finances better. Stay informed and make wise decisions.
28,655 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
If SpaceX joins the exclusive $2 trillion club, it would become the priciest stock among tech giants. This article un...
Fox Factory's Q4 2025 results shed light on demand for high-performance suspensions and the company’s margin discipli...
A high-profile legal clash over concert logistics shines a light on how money moves in the music business. This artic...
MP Materials sits at the intersection of U.S. manufacturing ambitions and global rare-earth supply. This guide breaks...
IBM argues that data gravity keeps information in place. This investing piece explains why that matters, how AI reinf...
A mailed bill payment altered can turn a routine payment into a costly fraud incident. This guide explains how it hap...
Aging homeowners are turning estate sales into a routine part of listings, prompting a need for a formal checklist re...
Rigetti Computing stock just took a sharp turn lower, surprising many investors who had hoped for a steady rise in a ...
A new, secretive cargo delivery concept tested by SpaceX could reshape global logistics. This investor-focused overvi...
NFL loyalty runs deep, but the families behind the game often carry unseen costs. This article digs into Mindy Armste...
As the Fed hints at slower rate moves, crypto markets stir. This guide explains what the federal reserve signals good...